BioVision introduces Human CellExp™ Recombinant Proteins

Representative Data
Representative Data
Spread the Word
Listed Under

Recombinant Proteins
Human cell expressed
Native state protein
Human Protein
Functional Protein


Milpitas - California - US


MILPITAS, Calif. - Jan. 16, 2014 - PRLog -- Biovision is very excited to introduce the Human CellExp™ Recombinant Proteins product line ( complementing our Proteins and Enzymes ( portfolio. Proteins, especially therapeutic proteins were initially extracted from human and animal tissues or blood. However, limitations in availability of the biological material, and the potential pathogen contaminations, led to the development of recombinant proteins traditionally produced in mammalian cells, insect cells, bacteria and yeast. Although this approach is very beneficial in terms of enhanced safety, lower immunogenicity, increased half-life and improved bioavailability, it is still hampered by the fact that these cells just do not have the machinery to produce authentic human proteins. Only a human cell can provide the micro-environment required to produce native human proteins.

Advantages of using human cells expression system:
The human cell factory gives access to the umpteen components like the enzymes, proteases, cellular organelles, and chaperone proteins necessary to properly process, modify, and fold the translated protein into the mature protein capable of carrying out its biological function in the context of the human system.

Disadvantages of using non-human cells expression system:
A non-human expression system can have important glycosylation differences that can significantly affect protein activity, function, and half-life and non-human glycosylation (like that carried out in the CHO expression system) can also cause immunogenicity problems.

BioVision is very pleased to offer Human CellExp™ Recombinant proteins, which will provide tremendous benefits for scientists performing human cell based studies.

The virtues of these proteins are:

•         They contain all the post-translational modifications (which affects     the activity, function and half-life) seen in human proteins.
•         They mimic native human proteins in terms of sub-unit assembly,     folding, secretion and other processes.
•         They show the same chemical & biological properties like stability, isoelectric point, solubility, binding affinities and biological activity.
•         They are produced in serum free medium; hence they exhibit minimal   batch to batch variability and are pathogen free products.
•         Applicable for basic and pre-clinical research

These proteins below to various categories including:
•         Cytokines: IL-2, IL-4, IL-6, IL-7, M-CSF, GM-CSF, CCL6, etc.
•         Growth Factors: FGFs, HGF, VEGF, TGFs, etc.
•         Biomarkers: PCSK9, DKK1, Serpins, Kallikreins, etc.
•         Enzymes: MMP1, 2, 9, PLAU, Urokinase, etc.

Applications of these proteins:
•         Protein-protein interaction studies
•         Protein-nucleic acid interaction studies
•         Functional analysis
•         Radio-Isotope labeling for structural analysis
•         Controls for Western blotting, ELISA, etc.
•         Sub-cellular localization studies
•         Stability analysis

In summary, BioVision offers a comprehensive line of Human CellExp™ Recombinant Proteins at the most competitive rates on the market.

Visit for this line of products.
Check out our flyer ( on these Human CellExp™ Recombinant Proteins

About BioVision:

BioVision, Inc. is a privately held Life Science company headquartered in the beautiful San Francisco Bay area. BioVision develops and offers a wide variety of products including assay kits, antibodies, recombinant proteins & enzymes, and other innovative research tools for studying Apoptosis, Metabolism, Cell Proliferation, Cellular Stress, Cell Damage and Repair, Diabetes, Obesity and Metabolic Syndrome, Stem Cell Biology, Gene Regulation, Signal Transduction, and more.

Venkat Bhat
BioVision, Inc. PRs
Trending News
Top Daily News
Top Weekly News

Like PRLog?
Click to Share